BridgeBio Pharma (BBIO) Income towards Parent Company (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Income towards Parent Company data on file, last reported at -$120.0 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 1.83% year-over-year to -$120.0 million; the trailing twelve-month figure through Mar 2026 stood at -$683.3 million (down 8.56% YoY), and the FY2025 full-year result was -$732.9 million, down 34.89% from the prior year.
• Income towards Parent Company climbed to -$120.0 million in Q1 2026, from -$194.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$35.0 million in Q1 2024 to a low of -$267.4 million in Q4 2024.
• A 5-year average of -$155.2 million and a median of -$164.3 million in 2024 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company soared 76.34% in 2024 and plunged 249.3% in 2025, its largest moves.
• Tracing BBIO's Income towards Parent Company over 5 years: stood at -$158.0 million in 2022, then declined by 28.04% to -$202.3 million in 2023, then plunged by 32.17% to -$267.4 million in 2024, then grew by 27.23% to -$194.6 million in 2025, then soared by 38.32% to -$120.0 million in 2026.
• Business Quant data shows BBIO's Income towards Parent Company at -$120.0 million in Q1 2026, -$194.6 million in Q4 2025, and -$184.9 million in Q3 2025.